Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Brand Name</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Leqembi</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Kisunla</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Aduhelm</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>CDR-SB Slowing</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>27% (0.45 pts)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>29-35% (iADRS)</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Marginal</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>None</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>None</td>
</tr>
<tr>
<td class="label">SAR228810</td>
<td>TBD</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>ARIA-E Risk</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Moderate (12.6%)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Higher (24%)</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>High (~35%)</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>High</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Low (~10%)</td>
</tr>
<tr>
<td class="label">SAR228810</td>
<td>TBD</td>
</tr>

Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Brand Name</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Leqembi</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Kisunla</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Aduhelm</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>CDR-SB Slowing</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>27% (0.45 pts)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>29-35% (iADRS)</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Marginal</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>None</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>None</td>
</tr>
<tr>
<td class="label">SAR228810</td>
<td>TBD</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>ARIA-E Risk</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Moderate (12.6%)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Higher (24%)</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>High (~35%)</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>High</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Low (~10%)</td>
</tr>
<tr>
<td class="label">SAR228810</td>
<td>TBD</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>All Anti-Amyloid Therapies</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Early AD (MCI-mild)</td>
</tr>
<tr>
<td class="label">Amyloid confirmation</td>
<td>Required</td>
</tr>
<tr>
<td class="label">Tau imaging</td>
<td>Recommended</td>
</tr>
<tr>
<td class="label">Age</td>
<td>Generally <85</td>
</tr>
<tr>
<td class="label">ApoE4 status</td>
<td>Risk factor for ARIA</td>
</tr>
<tr>
<td class="label">Anticoagulation</td>
<td>Caution</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Annual Cost (est.)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>~$28,000</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>~$32,000</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>~$28,000</td>
</tr>
</table>

Anti-amyloid immunotherapies represent a major therapeutic approach in Alzheimer's disease, targeting the amyloid-beta (Aβ) protein that is central to the amyloid hypothesis. This comparison matrix provides detailed information on six key immunotherapies: Lecanemab (Leqembi), Donanemab (Kisunla), Aducanumab (Aduhelm), Gantenerumab, Crenezumab, and SAR228810.

Overview Comparison Matrix

Detailed Comparison by Therapy

1. Lecanemab (Leqembi)

Mechanism of Action:
Lecanemab is a humanized IgG1 monoclonal antibody that selectively binds to Aβ protofibrils (soluble aggregated Aβ) with high affinity. It clears both protofibrils and plaques through Fc-mediated antibody-dependent cellular cytotoxicity (ADCC).

Target: Aβ protofibrils (soluble aggregates) and existing plaques

Phase 3 Trial - CLARITY-AD:

• Patient population: Early AD (MCI due to AD or mild AD dementia) with confirmed amyloid pathology
• Treatment duration: 18 months
• Primary endpoint: Change in CDR-SB: -0.45 vs placebo (27% slowing)
• Secondary endpoints: Amyloid PET SUVr reduction, ADAS-Cog14, ADCOMS
• Key results: Significant reduction in brain amyloid (Centiloids decrease), slowed clinical decline

ARIA Incidence:

• ARIA-E (edema): ~12.6%
• ARIA-H (hemorrhage): ~17.3%
• Most cases mild to moderate, manageable with monitoring

• 10 mg/kg IV infusion every 2 weeks
• Requires MRI monitoring at baseline, then weeks 5, 13, 27, 53

• Early AD (MCI or mild dementia)
• Confirmed amyloid pathology (PET or CSF)
• MMSE score 22-30
• No contraindication to MRI

2. Donanemab (Kisunla)

Mechanism of Action:
Donanemab is a monoclonal antibody that targets a specific conformational epitope on Aβ plaques. It binds to Aβ plaques and recruits microglia for plaque clearance through the brain's innate immune system.

Target: N-terminally truncated Aβ plaques (pyroglutamate-modified Aβ)

Phase 3 Trial - TRAILBLAZER-ALZ 2:

• Patient population: Early symptomatic AD with low/medium tau pathology
• Treatment duration: Up to 76 weeks (with optional treatment suspension)
• Primary endpoint: Change in iADRS: -6.02 vs placebo (35.1% slowing)
• Secondary endpoints: CDR-SB, amyloid PET, tau PET
• Key results: Most robust amyloid removal in class; possible treatment discontinuation after plaque clearance

ARIA Incidence:

• ARIA-E: ~24%
• ARIA-H: ~31%
• Higher than Lecanemab, but most manageable

• 350 mg infusion every 4 weeks (ramp-up: 3 initial doses at 700 mg then reduce)
• MRI monitoring at baseline, weeks 4, 12, 24, 52, then annually

• Early AD with confirmed amyloid
• Tau imaging (low/medium tau optimal benefit)
• Not recommended for rapid progressors

3. Aducanumab (Aduhelm)

Mechanism of Action:
Aducanumab is a human IgG1 monoclonal antibody that binds to multiple forms of Aβ, including monomers, oligomers, and plaques. It was designed to engage the immune system to clear amyloid plaques.

Target: Aβ plaques (broad-spectrum)

Phase 3 Trials - EMERGE and ENGAGE:

• Mixed results; EMERGE showed positive results at high dose
• Primary endpoint: CDR-SB change (delayed in EMERGE, not significant in ENGAGE at prespecified analysis)
• Key result: Amyloid removal significant but clinical benefit debated
• Re-analysis: Suggested benefit in higher dose arm

Note: Historic importance in field; raised bar for future approvals

4. Gantenerumab

Mechanism of Action:
Gantenerumab is a fully human IgG1 monoclonal antibody that binds with high affinity to Aβ plaques. It engages microglia-mediated clearance but showed limited efficacy in trials.

Target: Aβ plaques

Phase 3 Trials - GRADUATE 1 and 2:

• No significant clinical benefit in primary endpoints
• High rates of ARIA (brain edema and microhemorrhages)

FDA Status: Not approved; development discontinued

Note: Demonstrated amyloid removal but insufficient efficacy

5. Crenezumab

Mechanism of Action:
Crenezumab is a humanized IgG4 monoclonal antibody that preferentially targets Aβ oligomers and protofibrils. The IgG4 isotype reduces Fc-mediated effector functions, theoretically reducing ARIA risk.

Target: Aβ oligomers (soluble aggregated Aβ)

Phase 3 Trials - CREAD and CREAD2:
-did not meet primary endpoints

• No significant delays in clinical decline
• Lower ARIA rates than other antibodies

Note: Interesting proof-of-concept for oligomer-targeting

6. SAR228810

Mechanism of Action:
SAR228810 is a monoclonal antibody targeting Aβ protofibrils with high specificity. Development focused on early AD prevention.

Target: Aβ protofibrils

Phase 1/2 Trials:

• Completed early-phase trials
• Showed acceptable safety profile
• Limited public data on efficacy

Clinical Efficacy Comparison

Safety and Risk Profile Comparison

Patient Selection Criteria Summary

Economic and Access Considerations

Cross-Linking to Related Content

Alzheimer's Disease

The main [Alzheimer's Disease](/diseases/alzheimers-disease) disease page should reference this comparison matrix for treatment options.

Amyloid Immunotherapy

• [Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy): For comparison with Parkinson's immunotherapies
• [Tau Immunotherapy](/therapeutics/tau-immunotherapy): For comparison with tau-targeting approaches

Biomarkers

• [Amyloid PET Imaging](/biomarkers/amyloid-pet): For understanding amyloid detection
• [p-Tau Biomarkers](/biomarkers/p-tau-217): For understanding patient selection

Clinical Trials

• [Clinical Trials in Alzheimer's](/clinical-trials/alzheimers-trials): For trial listings

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
• [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7

Related Analyses:

• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;
• [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;